2021
Testicular Cancer Radiotherapy
Mahal A, Yu J. Testicular Cancer Radiotherapy. Practical Guides In Radiation Oncology 2021, 255-299. DOI: 10.1007/978-3-030-65137-4_12.Peer-Reviewed Original ResearchNonseminoma germ cell tumorsLymph node contouringExcellent survival outcomesGerm cell tumorsSequelae of radiotherapyTreatment planning considerationsDose reduction strategiesPrognostic indicators of relapseIndicator of relapseFollow-up protocolModern radiotherapyRadiotherapy managementRadiotherapy fieldGenitourinary malignanciesCell tumorsSurvival outcomesPrognostic indicatorReview epidemiologyTesticular cancerRadiation treatmentRadiotherapyNational guidelinesBony landmarksAnatomical fieldTreatment
2020
The Association Between the Affordable Care Act and Insurance Status, Stage and Treatment in Patients with Testicular Cancer.
Hsiang W, Han X, Jemal A, Nguyen KA, Shuch B, Park H, Yu JB, Gross CP, Davidoff AJ, Leapman MS. The Association Between the Affordable Care Act and Insurance Status, Stage and Treatment in Patients with Testicular Cancer. Urology Practice 2020, 7: 252-258. PMID: 34017908, PMCID: PMC8130174, DOI: 10.1097/upj.0000000000000109.Peer-Reviewed Original ResearchGerm cell tumorsTesticular germ cell tumorsProportion of patientsAffordable Care ActNon-expansion statesNational Cancer Data BaseExpansion statusState Medicaid expansion statusTesticular cancer patientsAdvanced-stage cancerLate-stage diagnosisLow-income patientsHealth insuranceCare ActMedicaid expansion statesMedicaid expansion statusDisease stageCancer patientsInsurance statusTesticular cancerCell tumorsPost-ACAMedicaid coveragePatientsMedicaid expansion
2019
RADI-34. USE OF LOW-DOSE STEREOTACTIC RADIOSURGERY FOR ADVANCED BRAIN METASTASES
Yang D, Yu J, Chiang V. RADI-34. USE OF LOW-DOSE STEREOTACTIC RADIOSURGERY FOR ADVANCED BRAIN METASTASES. Neuro-Oncology Advances 2019, 1: i28-i28. PMCID: PMC7213353, DOI: 10.1093/noajnl/vdz014.126.Peer-Reviewed Original ResearchGamma Knife stereotactic radiosurgeryBrain metastasesStereotactic radiosurgeryOverall survivalDisease progressionTime to disease progressionBRAF V600E tumorsMutation-targeted therapiesMedian overall survivalMetastatic melanoma patientsTreat brain metastasesPoor performance statusTumor controlMelanoma patientsSystemic therapyAdvanced diseasePerformance statusRe-treatmentTesticular cancerComposite endpointMetastasisSystemic agentsStudy exitImmunotherapyPatientsMP29-16 THE ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT, INSURANCE STATUS, AND TREATMENT AMONG PATIENTS WITH TESTICULAR CANCER
Hsiang W, Jemal A, Nguyen K, Shuch B, Park H, Yu J, Gross C, Davidoff A, Leapman* M. MP29-16 THE ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT, INSURANCE STATUS, AND TREATMENT AMONG PATIENTS WITH TESTICULAR CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557551.36748.5c.Peer-Reviewed Original Research